Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Haegarda Prior Authorization | OpenPayer
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0316

    Hereditary Angioedema - C1 Esterase Inhibitors (Subcutaneous)

    Customize your policy alerts

    Sign up for Cigna Policy IP0316 alerts

    Get alerted when Policy IP0316 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Haegarda (subcutaneous C1 esterase inhibitor [human]) used for routine prophylaxis of hereditary angioedema due to C1-INH deficiency. It applies to Cigna-administered health benefit plans, subject to the applicable benefit plan document and laws.

    Policy Summary
    PayerCigna
    PolicyHereditary Angioedema - C1 Esterase Inhibitors (Subcutaneous)
    Policy CodePolicy IP0316
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewNov 5, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of HAE type I or II, required laboratory findings, and specialist involvement.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added HCPCS code J0599 for injection of human C1 esterase inhibitor (Haegarda), 10 units.

    The policy added a requirement that the patient have hereditary angioedema type I or type II confirmed by specified diagnostic criteria.

    The policy removed the requirement for a confirmed pathogenic variant in the SERPING1, F12, ANGPT1, PLG, or KNG1 gene.

    The policy added a requirement involving a physician who specializes in the treatment of hereditary angioedema or related disorders.

    The policy added continuation criteria for patients currently receiving Haegarda prophylaxis.

    The policy removed the condition excluding episodes of angioedema with normal C1 inhibitor levels and function that were not related to a documented pathogenic variant in F12, ANGPT1, PLG, or KNG1.

    1 yearApproval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    60 IU/kg
    Maximum dose
    Twice weeklyAdministration frequency
    Types I or IICovered HAE subtypes
    <50%Baseline functional C1-INH

    Coverage Criteria

    HAE Due to C1-INH Deficiency — Prophylaxis

    Haegarda is considered medically necessary for 1 year when the patient has HAE due to C1-INH deficiency and meets the applicable initial or continuation pathway below.

    ONE of the following pathways

    • Initial therapy

      • Diagnostic confirmation of HAE type I or type II

        • The patient has low levels of functional C1-INH protein at baseline, as defined by laboratory reference values.< 50% of normal

          Documentation required.

        • The patient has lower-than-normal serum C4 levels at baseline, as defined by laboratory reference values.

          Documentation required.

      • The medication is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.
    • Continuation therapy

      • The patient is currently receiving Haegarda prophylaxis and has a diagnosis of HAE type I or type II.

        Documentation required. If the patient is currently receiving Haegarda but has not previously received approval through the Coverage Review Department, review under Initial Therapy criteria.

      • According to the prescriber, the patient has had a favorable clinical response since initiating Haegarda prophylactic therapy compared with baseline.

        Examples include decreased HAE acute attack frequency, decreased attack severity, or decreased duration of HAE attacks.

      • The medication is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.

    Dosing

    Haegarda dosing must remain within established policy limits.Maximum 60 IU/kg per injection
    Administer subcutaneously no more frequently than twice weekly, with doses separated by at least 3 days.At least 3 days between doses

    Continuation Therapy

    For continuation therapy, coverage requires that the patient is currently receiving Haegarda prophylaxis and meets all applicable continuation criteria.

    ALL of the following

    • The patient has a diagnosis of HAE type I or type II.

      Documentation required. HAE with normal C1-INH, also known as HAE type III, does not satisfy this requirement.

    • According to the prescriber, the patient has had a favorable clinical response since initiating Haegarda prophylactic therapy compared with baseline.

      Examples include decreased HAE acute attack frequency, decreased attack severity, or decreased duration of HAE attacks.

    • The medication is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.

    Haegarda is not covered for concomitant long-term prophylactic use with other HAE prophylactic therapies because combination therapy has not been studied and is not recommended. Examples include Cinryze, Orladeyo, and Takhzyro. Other medications, including Cinryze, may be used to treat acute HAE attacks or for short-term procedural prophylaxis.

    HAE with normal C1-INH, also known as HAE type III, does not satisfy the diagnostic requirement for coverage. Haegarda is not covered for HAE with normal C1-INH.

    Concomitant long-term prophylactic treatments for HAE, including Cinryze, Orladeyo, and Takhzyro, are not covered with Haegarda. These therapies may be used for acute attack treatment or short-term procedural prophylaxis when otherwise appropriate.

    Haegarda is not medically necessary for uses other than prophylaxis of HAE due to C1-INH deficiency. This list is not all-inclusive and may be updated as new published data become available.

    Coding and Laboratory Requirements

    Considered Medically NecessaryHCPCSCovered
    J0599Injection, C1 esterase inhibitor (human), (Haegarda), 10 units
    Baseline functional C1-INH
    ThresholdLess than 50% of normal functional C1-INH at baseline
    Reference standardMeasured according to laboratory reference values
    DocumentationBaseline laboratory results are required for initial therapy
    Baseline serum C4
    Required findingBaseline serum C4 must be lower than normal
    Reference standardMeasured according to laboratory reference values
    Documentation

    Provider Actions and Review Considerations

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Haegarda. Approval is available only when the applicable medical-necessity criteria and dosing requirements are met.

    Documentation Required

    Initial vs. Continuation Review

    Apply the appropriate review pathway based on the patient's treatment status. Patients previously approved through the Coverage Review Department and currently receiving Haegarda need only meet continuation criteria; patients currently receiving Haegarda without prior approval for the indication must meet initial-therapy criteria.

    • Initial therapy requires HAE type I or II diagnostic evidence and specialist prescribing or consultation.
    • Continuation therapy requires documented HAE type I or II, favorable clinical response, and specialist prescribing or consultation.

    Therapy Background

    Haegarda is a human plasma-derived C1 esterase inhibitor indicated for routine prophylaxis to prevent hereditary angioedema attacks in patients 6 years and older. The policy supports use for HAE types I and II associated with C1-INH deficiency.

    Clinical Definitions

    HAE type I or type II
    DefinitionHereditary angioedema due to C1-INH deficiency
    Diagnostic findingsLow functional C1-INH and low serum C4
    Covered subtypesHAE type I or type II
    HAE type III
    DefinitionHereditary angioedema with normal C1-INH
    Also known asHAE type III
    Coverage effectDoes not satisfy the diagnostic requirement for Haegarda coverage

    Initial Therapy Criteria

    Initial HAE Prophylaxis

    Approve Haegarda for 1 year when the patient meets ALL initial therapy requirements.

    Initial therapy

    • Functional C1-INH deficiency: The patient has low levels of functional C1-INH protein at baseline as defined by the laboratory reference values.< 50% of normal

      Documentation required.

    • Low serum C4: The patient has lower-than-normal serum C4 levels at baseline as defined by the laboratory reference values.Below the laboratory reference range

      Documentation required.

    Continuation Therapy Criteria

    Continuation Prophylaxis

    Approve Haegarda for 1 year when the patient is currently receiving Haegarda prophylaxis and meets ALL continuation requirements.

    Continuation prophylaxis

    • Current therapy: The patient is currently receiving Haegarda prophylaxis.

      If the patient has not previously received approval of Haegarda for this indication through the Coverage Review Department, initial therapy criteria must be met.

    • Diagnosis: The patient has HAE type I or type II.

      Documentation required; HAE with normal C1-INH does not satisfy the requirement.

    • Response: According to the prescriber, the patient has had a favorable clinical response since initiating Haegarda prophylaxis compared with baseline.

    Quantity and Frequency Limits

    Haegarda dosing limits
    Maximum doseUp to 60 IU/kg per injection
    Maximum frequencyNo more frequently than twice weekly
    Required intervalDoses must be separated by at least 3 days
    Policy Summary
    PayerCigna
    PolicyHereditary Angioedema - C1 Esterase Inhibitors (Subcutaneous)
    Policy CodePolicy IP0316
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewNov 5, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of HAE type I or II, required laboratory findings, and specialist involvement.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Laboratory RequirementsProvider Actions and Review ConsiderationsTherapy BackgroundClinical DefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaQuantity and Frequency Limits
    Baseline laboratory results are required for initial therapy
    Documentation Required

    Specialist Prescribing Requirement

    Haegarda must be prescribed by or in consultation with a physician who specializes in the condition being treated because of the specialized diagnostic, evaluation, and monitoring requirements.

    Documentation Required

    Required Clinical Documentation

    Submit documentation when the criteria identify it as required. Records must contain patient-specific identifying information and may include chart notes, laboratory records, and prescription claims records.

    • Provide the clinical records supporting the diagnosis and treatment request.
    • Include laboratory records when required by the diagnostic criteria.
    • Include prescription claims records when needed to establish current or prior therapy.
    Documentation Required

    Diagnostic Laboratory Evidence

    For initial therapy, document HAE type I or type II due to C1-INH deficiency with baseline laboratory evidence meeting the policy thresholds.

    • Functional C1-INH protein is less than 50% of normal at baseline, according to laboratory reference values.
    • Serum C4 is lower than normal at baseline, according to laboratory reference values.
    Documentation Required

    Continuation Response Documentation

    For continuation therapy, document HAE type I or type II and a favorable clinical response since Haegarda prophylaxis began compared with baseline.

    • Examples of favorable response include decreased acute attack frequency, decreased attack severity, or decreased attack duration.
    • Document the prescriber's assessment of the response and the relevant comparison with pretreatment baseline.
    Documentation Required

    Specialist Involvement

    Document that Haegarda is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in HAE or related disorders.

    • The specialist requirement applies to both initial and continuation therapy.
    • Include the specialist's role or consultation in the submitted clinical records.
    Documentation Required

    Clinical Documentation

    Clinical records must support the covered diagnosis and, when applicable, the patient's current Haegarda therapy. The documentation should establish HAE type I or II due to C1-INH deficiency and support the applicable initial or continuation pathway.

    • For initial requests, support the diagnostic criteria with baseline functional C1-INH and serum C4 results.
    • For continuation requests, support current Haegarda prophylaxis, HAE type I or II, and favorable response.
    Denial Risk

    HAE Type III Not Eligible

    HAE with normal C1-INH, also known as HAE type III, does not satisfy the covered diagnostic requirement for Haegarda prophylaxis.

    Denial Risk

    Concurrent HAE Prophylaxis

    Concomitant use of Haegarda with another long-term HAE prophylactic therapy is not medically necessary because combination prophylaxis has not been studied and is not recommended.

    • Examples include Cinryze, Orladeyo, and Takhzyro.
    • Other therapies may be used for acute HAE attacks or short-term procedural prophylaxis when clinically appropriate.
    Denial Risk

    Uncovered Uses

    Haegarda is not medically necessary for uses other than prophylaxis of HAE due to C1-INH deficiency.

    • Requests must be for the covered prophylaxis indication.
    • HAE with normal C1-INH and other noncovered uses do not meet the policy indication.
    Denial Risk

    Excessive Dose or Frequency

    Flag requests exceeding the established dosing limits for clinical review. Standard dosing is limited to 60 IU/kg per injection, administered no more frequently than twice weekly, with doses separated by at least 3 days.

    • Maximum: 60 IU/kg per injection.
    • Frequency: no more than twice weekly.
    • Dose interval: at least 3 days apart.
    • Doses outside these limits are considered case by case by a clinician, such as a Medical Director or Pharmacist.
    Denial Risk

    Unsupported HAE Type

    Coverage may be denied when Haegarda is requested for a patient with HAE with normal C1 inhibitor, also known as HAE type III, because the policy requires HAE type I or II due to C1-INH deficiency.

    • Support the diagnosis with the required functional C1-INH and serum C4 findings for initial therapy.
    • A normal C1-INH-related diagnosis does not satisfy the covered diagnostic requirement.
    Denial Risk

    Concurrent HAE Treatment

    Concomitant use of Haegarda with other HAE treatments for long-term prophylaxis is not covered as medically necessary.

    • Examples include Cinryze, Takhzyro, and Orladeyo.
    • Do not approve concurrent long-term prophylactic use with another HAE prophylactic therapy.
    Favorable clinical response
    DefinitionA reduction in acute HAE attack frequency, severity, or duration
    Comparison pointCompared with the period before prophylactic therapy
    ExamplesFewer attacks, less severe attacks, or shorter attack duration
    HAE type III and coverage eligibility
    DefinitionHereditary angioedema with normal C1 inhibitor
    Also known asHAE type III
    Coverage eligibilityDoes not satisfy the policy's diagnostic requirement for HAE type I or type II
    Specialist involvement:
    Haegarda is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.

    Initial Haegarda Prophylaxis

    Initial coverage requires confirmation of hereditary angioedema type I or type II.

    Diagnostic confirmation: The patient has HAE type I or type II as confirmed by the applicable diagnostic criteria.Functional C1-INH < 50% of normal at baseline and serum C4 below the laboratory reference range

    HAE with normal C1 inhibitor, also known as HAE type III, does not satisfy this requirement. Documentation is required.

    Examples include decreased HAE attack frequency, severity, or duration.

  1. Prescriber qualification: Haegarda is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.
  2. Haegarda Continuation Therapy

    Continuation criteria apply to patients currently receiving Haegarda prophylaxis.

    Haegarda continuation therapy

    • Current Haegarda prophylaxis: The patient is currently receiving Haegarda prophylaxis.
    • Covered diagnosis: The patient has HAE type I or type II.

      HAE with normal C1-INH, also known as HAE type III, does not satisfy the diagnostic requirement.

    • Favorable response: According to the prescriber, the patient has had a favorable clinical response since initiating Haegarda prophylaxis compared with baseline.

      Examples include decreased attack frequency, attack severity, or attack duration.

    • Specialist involvement: Haegarda is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.